Sat.Dec 07, 2024

article thumbnail

Rilzabrutinib Improves Platelet Response, Quality of Life in Immune Thrombocytopenia Compared to Placebo

HCPLive

Notably, participants without platelet responses also experienced improvements in fatigue, which may be due to the monoclonal antibodys anti-inflammatory action.

article thumbnail

Hydroxyurea Shows Clinical Benefit in HbSC, Misses the Mark on Safety

HCPLive

While the therapy was generally well-tolerated, the PIVOT trial failed its primary endpoint of dose-limiting toxicities.

52
article thumbnail

FDA News Month in Review: November 2024

HCPLive

This new edition of HCPLives monthly newsletter on recent US Food and Drug Administration (FDA) news features highlighted updates from across therapeutic pipelines.

52
article thumbnail

Etavopivat Well-Tolerated With Some Disease-Modifying Activity in SCD

HCPLive

The therapy uses a novel pyruvate kinase activator mechanism and warrants further investigation in an ongoing phase 3 trial.

52
article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!